MTH-68/H oncolytic viral treatment in human high-grade gliomas

Journal of Neuro-Oncology

Volumn 67, Issue 1-2, 2004, Pages 83-93

  Csatary, L K ^a   Gosztonyi, G ^b   Szeberenyi, J ^c   Fabian, Z ^c   Liszka, V ^a   Bodey, B ^d,e   Csatary, C M ^a  

^a United Cancer Research Institute   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF PÉCS   (Hungary)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

Apoptosis; Chemotherapy; Glioblastoma multiforme (GBM); High grade glioma; MTH 68 H; Newcastle disease virus (NDV); Programmed cell death (PCD); Virus therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ETOPOSIDE; FLUOROURACIL; GABAPENTIN; LIVE VACCINE; MTH 68 H; ONCOLYTIC VIRUS; PHENYTOIN; TAMOXIFEN; THALIDOMIDE; UNCLASSIFIED DRUG; VALPROATE SEMISODIUM; VINCRISTINE;

ADULT; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASE REPORT; DAILY LIFE ACTIVITY; DISEASE DURATION; FEMALE; GLIOBLASTOMA; HUMAN; LIFESTYLE; MALE; NEUROECTODERM TUMOR; NEWCASTLE DISEASE PARAMYXOVIRUS; PROGNOSIS; QUALITY OF LIFE; REVIEW; SCHOOL CHILD; SEIZURE; SIDE EFFECT; TREATMENT FAILURE; VIRUS STRAIN;

BRAIN NEOPLASMS; CHILD; FEMALE; GLIOMA; HUMANS; INFANT; INJECTIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEWCASTLE DISEASE VIRUS; QUALITY OF LIFE; VIRAL VACCINES;

EID: 1842484851     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:NEON.0000021735.85511.05     Document Type: Review

References (62)

1. Simons JW: The Nemunaitis article reviewed: live viruses in cancer treatment. Oncology 16: 1496-1497, 2002
2. Bodey B, Bodey B Jr, Siegel SE: Immunophenotypical (IP) differential diagnosis and immunobiology of childhood primary brain tumors. A decade of experience. J Pediatric Hematol Oncol 6: 65-84, 1998
3. von Deimling A, Louis DN, Wiestler OD: Molecular pathways in the formation of gliomas. Glia 15: 328-338, 1995
4. Kleihues P, Soylemezoglu F, Schauble B, Scheithauer BW, Burger PC: Histopathology, classification, and grading of gliomas. Glia 15: 211-221, 1995
5. Katsura S, Susuki J, Wada T: Statistical study of brain tumours in the neurosurgical clinics in Japan. J Neurosurg 16: 570-580, 1959
6. Cairncross JG: The biology of astrocytoma: lessons learned from chronic myelogenous leukemia-hypothesis. J Neuro-Oncol 5: 99-104, 1987
7. Bodey B, Zeltzer PM, Saldivar V, Kemshead J: Immunophenotyping of childhood astrocytomas with a library of monoclonal antibodies. Int J Cancer 45: 1079-1087, 1990
8. Bullard DE, Gillespie Y, Mahaley MS, Bigner DD: Immunobiology of human gliomas. Semin Oncol 13: 94-109, 1986
9. Ohgaki K, Schäuble B, zur Hausen A, von Ammon K, Kleihues P: Genetic alterations associated with the evolution and progression of astrocytic brain tumors. Virchow Arch 427: 113-118, 1995
10. Bodey B, Gröger AM, Bodey B Jr, Siegel SE, Kaiser HE: Immunocytochemical detection of p53 protein expression in various childhood astrocytoma subtypes: Significance in tumor progression. Anticancer Res 17: 1187-1194, 1997
11. von Deimling A, von Ammon K, Schoenfeld D, Wiestler OD, Seizinger BR, Louis DN: Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 3: 19-26, 1993
12. Biernat W, Kleihues P, Yonekawa Y, Ohgaki H: Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. J Neuropathol Exp Neurol 56: 180-185, 1997
13. Watanabe K, Tachibana O, Sato K, Yonekawa Y, Kleihues P, Ohgaki H: Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6: 217-223, 1996
14. Watanabe K, Tachibana O, Yonekawa Y, Kleihues P, Ohgaki H: Role of gemistocytes in astrocytoma progression. Lab Invest 76: 277-284, 1997
15. Pollack IF, Campbell JW, Hamilton RL, Martinez AJ, Bozik ME: Proliferation index as a predictor of prognosis in malignant gliomas of childhood. Cancer 79: 849-856, 1997
16. Webb HE, Gordon Smith CE: Viruses in the treatment of cancer. Lancet 1: 1206-1208, 1970
17. Driever PH, Rabkin SD (eds): Replication-Competent Viruses for Cancer Therapy. Monographs in Virology. Vol 22. Karger, Basel, 2001
18. Nemunaitis J: Live viruses in cancer treatment. Oncology 16: 1483-1492, 2002
19. Nelson NJ: Viruses and cancer. J Natl Cancer Inst 91: 1709, 1999
20. Cassell WA, Garrett RE: Newcastle disease virus as an antineoplastic agent. Cancer 18: 863-868, 1965
21. Csatary LK: Viruses in the treatment of cancer. Lancet 2: 825, 1971
22. Csatary LK, Eckhardt S, Bukosza I, Czegledi F, Fenyvesi C, Gergely P, Bodey B, Csatary CM: Attenuated veterinary virus vaccine for the treatment of cancer. Cancer Detect Prev 17: 619-627, 1993
23. Csatary LK, Csatary E, Moss RW: Scientific interest in Newcastle disease virus is reviving. J Natl Cancer Inst 92: 493-494, 2000
24. Csatary LK, Moss RW, Beuth J, Töröcsik B, Szeberenyi J, Bakacs T: Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68/H). Anticancer Res 19: 635-638, 1999
25. Fabian Z, Töröcsik B, Csatary LK, Kiss K, Szeberenyi J: Induction of apoptosis by a Newcastle disease virus vaccine (MTH-68/H) in PC12 rat phaeochromocytoma cells. Anticancer Res 21: 125-136, 2001
26. Szeberenyi J, Fabian Z, Töröcsik B, Kiss K, Csatary LK: Newcastle disease virus-induced apoptosis in PC12 pheochromocytoma cells. Am J Therap 10(4): 282-288, 2003
27. Csatary LK, Bakacs T: Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma. JAMA 281: 1588-1589, 1999
28. Steiner HH, Herold-Mende Ch, Bonsanto M, Geletneky K, Kunze S: Zur Prognose von Hirntumoren: Epidemiologie, Überlebenszeit und klinischer Verlauf. Versicherungsmedizin 50: 173-179, 1998
29. Chamberlain MC, Kormanik PA: Practical guidelines for the treatment of malignant gliomas. West J Med 168: 114-120, 1998
30. Puzzilli F, Ruggeri A, Mastronadi L, Di Stefano D, Lunardi D: Long-term survival in cerebral glioblastoma. Case report and critical review of the literature. Tumori 84: 69-74, 1998
31. Pollak L, Gur R, Walach N, Reif R, Tamir L, Schiffer J: Clinical determinants of long-term survival in patients with glioblastoma multiforme. Tumori 83: 613-617, 1997
32. Salvati M, Cervoni L, Artico M, Caruso R, Gagliardi FM: Long-term survival in patents with supratentorial glioblastoma. J Neuro-Oncol 36: 61-64, 1998
33. Yoshida T, Kawano N, Oka H, Fujii K, Nakazato Y: Clinical cure of glioblastoma - two case reports. Neurol Med Chir (Tokyo) 40: 224-229, 2000
34. Klein R, Molenkamp G, Sorensen N, Roggendorf W: Favorable outcome of giant cell glioblastoma in a child. Report of an 11-year survival period. Childs Nerv Syst 14: 288-291, 1998
35. Meyer-Puttlitz B, Hayashi Y, Wahaa A, Rollbrocker B, Boström J, Wiestler OD, Louis DN, Reifenberger G, von Deimling A: Molecular genetic analysis of giant cell glioblastomas. Am J Pathol 151: 853-857, 1997
36. Roth W, Weller M: Chemotherapy and immunotherapy of malignant glioma: molecular mechanisms and clinical perspectives. Cell Mol Life Sci 56: 481-506, 1999
37. Fillmore HL, VanMeter TE, Broaddus WC: Membrane-type matrix metalloproteinases (MT-MMPs): expression and function during glioma invasion. J Neuro-Oncol 53: 187-202, 2001
38. Hosli P, Sappino AP, de Tribolet N, Dietrich PY: Malignant glioma: should chemotherapy be overthrown by experimental treatments? Ann Oncol 9: 589-600, 1998
39. Alemany R, Gomez-Manzano C, Balague C, Yung WK, Curiel DT, Kyritsis AP, Fueyo J: Gene therapy for glioblastomas: molecular targets, adenoviral vectors, and oncolytic adenoviruses. Exp Cell Res 252: 1-12, 1999
40. Burton EC, Prados MD: Malignant gliomas. Curr Treat Options Oncol 1: 459-468, 2000
41. Markert JM, Gillespie GY, Weichselbaum RR, Roizman B, Whitley RJ: Genetically engineered HSV in the treatment of glioma: a review. Rev Med Virol 10: 17-30, 2000
42. Mahaley Jr MS, Bigner DD, Dudka LF, Wilds PR, Williams DH, Bouldin TW, Whitaker JN, Bynum JM: Immunobiology of primary intracranial tumors. Part 7: Active immunization of patients with anaplastic glioma cells: a pilot study. J Neurosurg 59: 201-207, 1983
43. Mahaley MS, Gillespie GY, Gillespie RP, Watkins PJ, Bigner DD, Wikstrand CJ, MacQueen JM, Sanfilippo F: Immunobiology of primary intracranial tumors. Part 8: serological responses to active immunization of patients with anaplastic gliomas. J Neurosurg 59: 208-216, 1983
44. Bodey B: Spontaneous regression of neoplasms: new possibilities for immunotherapy. Expert Opin Biol Ther 2: 459-476, 2002
45. Tunici P, Gianni D, Finocchiaro G: Gene therapy of glioblastomas: from suicide to homicide. Prog Brain Res 132: 711-719, 2001
46. Schluesener HJ, Meyermann R, Deininger M: Immune responses in glioblastoma: an avenue to effective cancer therapy or a mere epiphenomenon? CTMI 265: 259-267, 2002
47. Karpati G, Li H, Nalbantoglu J: Molecular therapy for glioblastoma. Curr Opin Mol Ther 1: 545-552, 1999
48. Lorence RM, Roberts MS, Groene WS, Rabin H: Replication-competent, oncolytic Newcastle disease virus for cancer therapy. In: Driever PH, Rabkin SD (eds): Replication-Competent Viruses for Cancer Therapy. Monographs in Virology, Vol 22. Doerr HW, Karger, 2001, 160-182
49. Reichard KW, Lorence RM, Cascino CJ: Selective replication of Newcastle disease virus (NDV) in cancer cells is associated with virus-induced cell fusion. Proc Am Assoc Cancer Res 33: 521, 1992
50. Pennisi E: Training viruses to attack cancers. Science 282: 1244-1246, 1998
51. Nelson NJ: Scientific interest in Newcastle disease virus is reviving. Viruses and cancer. J Natl Cancer Inst 91: 1708-1710, 1999
52. Reichard KW, Lorence RM, Cascino CJ, Peeples ME, Walter RJ, Fernando MB, Reyes HM, Greager JA: Newcastle disease virus selectively kills human tumor cells. J Surg Res 52: 448-453, 1992
53. von Deimling A, von Ammon K, Schoenfeld D, Wiestler OD, Seizinger BR, Louis DN: Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 3: 19-26, 1993
54. Watanabe K, Tachinaba O, Sato K, Yonekawa Y, Kleihues P, Ohgaki H: Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6: 217-224, 1996
55. Biernat W, Kleihues P, Yonekawa Y, Ohgaki H: Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. J Neuropath Exp Neurol 56: 180-185, 1997
56. Fazakerley J, Allsopp TE: Programmed cell death in virus intections of the nervous system. In: Gosztonyi G (ed) The Mechanisms of Neuronal Damage in Virus Infections of the Nervous System. CTMI 253: 95-119 (2001)
57. Fueyo J, Alemany R, Gomez-Marzano C, Fuller GN, Khan A, Conrad CA, Liu TJ, Jiang H, Lemoine MG, Suzuki K, Sawaya R, Curiel DT, Alfred Yung WK, Lang FF: Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Ntl Cancer Inst 95: 652-660, 2003
58. Reichard KW, Lorence RM, Katubig BB, Peeples ME, Reyes HM: Retinoic acid enhances killing of neuroblastoma cells by Newcastle disease virus. J Pediatr Surg 28: 1221-1225, 1993
59. Lorence RM, Katubig BB, Reichard KW, Reyes HM, Phuangsab A, Sassetti MD, Walter RJ, Peeples ME: Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. Cancer Res 54: 6017-6021, 1994
60. Lam KM: Apoptosis is chicken embryo fibroblasts caused by Newcastle disease virus. Vet Microbiol 47: 357-363, 1995
61. Lam KM, Vasconcelos AC, Bickford AA: Apoptosis as a cause of death in chicken embryos inoculated with Newcastle disease virus. Microb Pathol 19: 169-174, 1995
62. Reichard KW, Lorence RM, Cascino CJ: Selective replication of Newcastle disease virus (NDV) in cancer cells is associated with virus-induced cell fusion. Proc Am Assoc Cancer Res 33: 521, 1992